Lupin gets USFDA nod to market Wilson disease treatment drug
Pharma major Lupin Limited announced on Friday that United States Food and Drug Administration (USFDA) had given the company approval for its Trientine Hydrochloride capsules USP, 250 mg. The company will now be able to market a generic equivalent of Syprine capsules, 250 mg of Bausch Health US, LLC.
Trientine Hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant to Penicillamine. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility in India.
According to data from IMS Health and Quintiles (IQVIA) for the month of March 2020, Trientine Hydrochloride capsules USP had annual sales of approximately US$ 86 million in the US.
Lupin is an innovation-led transnational pharmaceutical company, developing and delivering a wide range of branded and generic formulations, biosimilar products, and APIs, globally.
On Friday, the stock closed at Rs 892.85, up by 0.80 per cent or Rs 7.15 per share. The 52-week high is recorded at Rs 906.35 and the 52-week low is Rs 505 on BSE.